Advertisement
Canada markets close in 5 hours 36 minutes
  • S&P/TSX

    21,721.00
    -152.72 (-0.70%)
     
  • S&P 500

    5,010.87
    -60.76 (-1.20%)
     
  • DOW

    37,829.83
    -631.09 (-1.64%)
     
  • CAD/USD

    0.7295
    -0.0003 (-0.04%)
     
  • CRUDE OIL

    82.42
    -0.39 (-0.47%)
     
  • Bitcoin CAD

    87,365.21
    -3,006.02 (-3.33%)
     
  • CMC Crypto 200

    1,374.48
    -8.09 (-0.59%)
     
  • GOLD FUTURES

    2,332.90
    -5.50 (-0.24%)
     
  • RUSSELL 2000

    1,961.45
    -33.98 (-1.70%)
     
  • 10-Yr Bond

    4.7270
    +0.0750 (+1.61%)
     
  • NASDAQ

    15,493.67
    -219.07 (-1.39%)
     
  • VOLATILITY

    17.37
    +1.40 (+8.78%)
     
  • FTSE

    8,051.54
    +11.16 (+0.14%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6806
    -0.0013 (-0.19%)
     

Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years

Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years

Gilead Sciences (NASDAQ: GILD) has a bright future ahead with HIV treatment Sunlenca obtaining approval from the Food and Drug Administration last year and cancer drug Trodelvy continuing to show strong growth. Why has Gilead Sciences stock struggled? The simple reason for Gilead's woes is that the business has had trouble generating growth.